May 24, 2023 – Claudin-18.2 Emerges as a Novel Therapeutic Target in GI Malignancies

CLAUDIN-18 Splice Variant 2 (claudin-18.2; CLDN18.2) has become a promising target for the treatment of patients with digestive malignancies, such as gastric cancer (GC), gastroesophageal junction (GEJ) cancer, esophageal cancer, and pancreatic cancer, because of its limited expression in healthy tissues and abnormal overexpression in a range of malignancies.1 Multiple clinical trials of CLDN18.2-targeted therapies, including…

Read More

May 19, 2023 – GEN-001/Avelumab Combination Induces Antitumor Activity in Gastric and GEJ Cancer

Treatment with avelumab (Bavencio) plus GEN-001 in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma has demonstrated positive antitumor activity, according to an announcement by Genome & Company.1 The finding comes from a phase 2 study (NCT05419362) of GEN-001 in combination with avelumab, for which the primary end point is objective response rate (ORR),…

Read More

May 19, 2023 – CARsgen begins trial of CAR T-cell therapy for gastric cancer

Chinese biotechnology company CARsgen Therapeutics has started a Phase II clinical trial of CT041 in the US, enrolling patients with Claudin18.2 (CLDN18.2) positive advanced gastric cancer/gastroesophageal junction cancer (GC/GEJ). CT041 is an autologous chimeric antigen receptor (CAR) T-cell product candidate that targets the CLDN18.2 protein. The trial will evaluate CT041 in treating individuals with CLDN18.2…

Read More

April 26, 2023 – Novel Gastric Cancer Drug Under FDA Review Improves Survival

A treatment currently under review by the Food and Drug Administration (FDA) for the treatment of patients with advanced unresectable or metastatic gastric or gastroesophageal junction (G/GEJ) adenocarcinoma has been shown to improve patients’ overall survival, according to an announcement from the biotechnology company behind the treatment. Interim results of the RATIONALE 305 study showed…

Read More